Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +60

Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock - Yahoo Finance

AI-generated analysis

πŸ“ˆ Gilead Sciences (GILD) ranks 4th among the 14 best defensive stocks recommended for investment.

πŸ’Š The company has transitioned from volatile COVID-19 revenue to high-visibility earnings driven by HIV and oncology.

πŸ›‘οΈ Gilead maintains a dominant HIV market position providing predictable, non-discretionary cash flow similar to a utility.

⏳ Management confirmed no major loss of drug exclusivity until 2036, offering significant safety in the pharma sector.

πŸ’° Quarterly dividends were raised to $0.82 per share with a forward yield standing at approximately 2.4%.

πŸ”¬ Oncology now accounts for about 12% of total revenue, driven by products like Trodelvy and cell therapies.

πŸ“Š The company is currently trading at a Forward P/E ratio of 14.95, which is lower than the industry average of 20.74.

🧭 Shares recently rose 1.55% to $130.84, outperforming the S&P 500 and the broader medical sector.

πŸ“… Analysts project full-year EPS of $8.62 per share with revenue growth expected to reach $30.15 billion.

⚠️ Gilead Sciences currently holds a Zacks Rank of #3, classified as a "Hold" based on recent estimate adjustments.

🌐 The medical-biomedical industry averages a PEG ratio of 1.4 while Gilead's current PEG ratio is 1.7.

Bullish Signals
  • Gilead Sciences' HIV portfolio generated $20.8 billion in revenue for 2025, demonstrating strong financial performance despite the transition away from COVID-19 treatment.
  • The company's dominant position in HIV provides high-visibility, non-discretionary earnings that function like a utility with predictable cash flow unaffected by economic cycles.
  • CFO Andrew Dickinson emphasized at the Barclays Healthcare Conference in March that Gilead faces no major loss of exclusivity until 2036, offering long-term safety.
  • Yeztugo, the first twice-yearly HIV prevention therapy, is expected to hit $800 million in sales in 2026, adding a new growth driver.
  • Gilead raised its quarterly dividend to $0.82 per share in February, marking another year of consecutive growth and supporting its attractive 2.4% forward dividend yield.
  • Non-GAAP EPS guidance stands at $8.45–$8.85 for the full year, backed by a healthy balance sheet and cash return to shareholders.
  • Oncology now accounts for about 12% of total revenue with products like Trodelvy and cell therapies seeing double-digit growth, providing a high-growth kicker to the defensive HIV base.
  • Gilead Sciences was up +1.55% at $130.84 in its latest close session, outpacing the S&P 500's 1.02% gain on the day.
  • Zacks Consensus Estimates project full year earnings of $8.62 per share and revenue of $30.15 billion, representing growth of +5.77% and +2.39%, respectively.
  • Gilead Sciences is being traded at a Forward P/E ratio of 14.95, which is significantly below the industry average of 20.74, indicating a valuation discount.
Risk Factors
  • Gilead's Zacks Industry Rank is 144 out of over 250 industries, placing it within the bottom 41%.
  • The PEG ratio is 1.7, compared to an industry average of 1.4 for Medical - Biomedical and Genetics, suggesting the stock may be less attractive relative to growth prospects.
  • Over the past month, the Zacks Consensus EPS estimate has moved 0.45% lower, indicating recent downward revisions in analyst expectations.
  • Gilead Sciences is currently held with a Zacks Rank #3 (Hold), rather than being rated as a Strong Buy or better.
Full Analysis
Gilead Sciences, Inc. (NASDAQ:GILD) has been highlighted as the fourth-ranked entry in a list of 14 defensive stocks, primarily due to its strong cash flow stability driven by its dominant position in the HIV market. The company's revenue from its HIV portfolio reached $20.8 billion in 2025, providing predictable earnings because treatments are life-sustaining and patients rarely switch therapies once stabilized. CFO Andrew Dickinson noted at the Barclays Healthcare Conference in March that Gilead faces no significant loss of exclusivity until 2036, offering a rare safety runway in the pharmaceutical sector. Additionally, Yeztugo, its first twice-yearly HIV prevention therapy, is projected to generate $800 million in sales in 2026. To enhance its defensive profile, Gilead has diversified into oncology over the last five years, which currently accounts for approximately 12% of total revenue with products like Trodelvy and cell therapies showing double-digit growth. The stock is favored by income-focused funds following a board decision in February to raise the quarterly dividend to $0.82 per share, marking consecutive annual growth. As of April, the forward dividend yield stands at approximately 2.4%, supported by non-GAAP EPS guidance between $8.45 and $8.85 for the full year. Valuation metrics indicate Gilead is trading at a discount compared to its industry average, with a Forward P/E ratio of 14.95 versus an industry average of 20.74. The company carries a market capitalization of $159.9 billion and currently trades at a PEG ratio of 1.7. However, the Zacks Industry Rank for the Medical - Biomedical and Genetics sector is 144, placing it within the bottom 41% of over 250 industries. For the full year 2026, Zacks Consensus Estimates project earnings of $8.62 per share with net sales of $30.15 billion. Gilead is currently assigned a Zacks Rank #3 (Hold), though consensus EPS estimates have moved 0.45% lower recently. The investment community will closely monitor the upcoming earnings report scheduled for May 7, 2026, with expectations for quarterly EPS of $1.89 and revenue of $6.89 billion. While Gilead outperformed the S&P 500 in recent trading sessions, rising to +1.55% against a sector gain of 1.69%, the article notes that certain AI stocks may offer greater upside potential. The Zacks Investment Research model suggests tracking estimate revisions as they correlate with stock price performance, noting that #1 ranked stocks have contributed an average annual return of 25% since 1988.